Immune landscape and biomarkers for immuno-oncology in colorectal cancers

키워드

참고문헌 (72)

1. 정규원, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2016", Cancer Research and Treatment, 51(2), pp.417~430 (2019), 대한암학회
2. Siegel RL, "Colorectal cancer statistics, 2017", CA Cancer J Clin, 67, pp.177~193 (2017)
3. Bae JM, "Distinct clinical outcomes of two CIMP-positive colorectal cancer subtypes based on a revised CIMP classification system", Br J Cancer, 116, pp.1012~1020 (2017)
4. Fridman WH, "The immune contexture in cancer prognosis and treatment", Nat Rev Clin Oncol, 14, pp.717~734 (2017)
5. Hodi FS, "Improved survival with ipilimumab in patients with metastatic melanoma", N Engl J Med, 363, pp.711~723 (2010)
6. Garon EB, "Pembrolizumab for the treatment of non-small-cell lung cancer", N Engl J Med, 372, pp.2018~2028 (2015)
7. Le DT, "PD-1 blockade in tumors with mismatch-repair deficiency", N Engl J Med, 372, pp.2509~2520 (2015)
8. Overman MJ, "Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer(CheckMate 142) : an open-label, multicentre, phase 2 study", Lancet Oncol, 18, pp.1182~1191 (2017)
9. Spratt JS Jr, "Prevalence and prognosis of individual clinical and pathologic variables associated with colorectal carcinoma", Cancer, 20, pp.1976~1985 (1967)
10. Watt AG, "Colonic carcinoma : a quantitative assessment of lymphocyte infiltration at the periphery of colonic tumors related to prognosis", Cancer, 41, pp.279~282 (1978)
11. Pihl E, "Immunomorphological features of prognostic significance in Dukes'Class B colorectal carcinoma", Cancer Res, 37, pp.4145~4149 (1977)
12. Maoz A, "The Crohn's-like lymphoid reaction to colorectal cancer-tertiary lymphoid structures with immunologic and potentially therapeutic relevance in colorectal cancer", Front Immunol, 10, pp.1884~ (2019)
13. Naito Y, "CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer", Cancer Res, 58, pp.3491~3494 (1998)
14. Ogino S, "Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype", Clin Cancer Res, 15, pp.6412~6420 (2009)
15. Nearchou IP, "Automated analysis of lymphocytic infiltration, tumor budding, and their spatial relationship improves prognostic accuracy in colorectal cancer", Cancer Immunol Res, 7, pp.609~620 (2019)
16. Galon J, "Type, density, and location of immune cells within human colorectal tumors predict clinical outcome", Science, 313, pp.1960~1964 (2006)
17. Anitei MG, "Prognostic and predictive values of the immunoscore in patients with rectal cancer", Clin Cancer Res, 20, pp.1891~1899 (2014)
18. Mlecnik B, "Integrative analyses of colorectal cancer show immunoscore is a stronger predictor of patient survival than microsatellite instability", Immunity, 44, pp.698~711 (2016)
19. Mlecnik B, "Comprehensive intrametastatic immune quantification and major impact of immunoscore on survival", J Natl Cancer Inst, 110, pp.97~108 (2018)
20. Pages F, "International validation of the consensus immunoscore for the classification of colon cancer : a prognostic and accuracy study", Lancet, 391, pp.2128~2139 (2018)
21. Reichling C, "Artificial intelligence-guided tissue analysis combined with immune infiltrate assessment predicts stage III colon cancer outcomes in PETACC08 study", Gut, 69, pp.681~690 (2020)
22. Yoo SY, "Whole-slide image analysis reveals quantitative landscape of tumor-immune microenvironment in colorectal cancers", Clin Cancer Res, 26, pp.870~881 (2020)
23. Guinney J, "The consensus molecular subtypes of colorectal cancer", Nat Med, 21, pp.1350~1356 (2015)
24. Becht E, "Immune and stromal classification of colorectal cancer is associated with molecular subtypes and relevant for precision immunotherapy", Clin Cancer Res, 22, pp.4057~4066 (2016)
25. Newman AM, "Robust enumeration of cell subsets from tissue expression profiles", Nat Methods, 12, pp.453~457 (2015)
26. Aran D, "xCell : digitally portraying the tissue cellular heterogeneity landscape", Genome Biol, 18, pp.220~ (2017)
27. Becht E, "Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression", Genome Biol, 17, pp.218~ (2016)
28. Jimenez-Sanchez A, "Comprehensive benchmarking and integration of tumor microenvironment cell estimation methods", Cancer Res, 79, pp.6238~6246 (2019)
29. Labib M, "Single-cell analysis targeting the proteome", Nat Rev Chem, 4, pp.143~158 (2020)
30. Zhang L, "Recharacterizing tumor-infiltrating lymphocytes by single-cell RNA sequencing", Cancer Immunol Res, 7, pp.1040~1046 (2019)
31. Moncada R, "Integrating microarraybased spatial transcriptomics and single-cell RNA-seq reveals tissue architecture in pancreatic ductal adenocarcinomas", Nat Biotechnol, 38, pp.333~342 (2020)
32. Jackson HW, "The single-cell pathology landscape of breast cancer", Nature, 578, pp.615~620 (2020)
33. Xiong Y, "Profiles of immune infiltration in colorectal cancer and their clinical significant : a gene expression-based study", Cancer Med, 7, pp.4496~4508 (2018)
34. Marisa L, "The balance between cytotoxic T-cell lymphocytes and immune checkpoint expression in the prognosis of colon tumors", J Natl Cancer Inst, 110, pp.68~77 (2018)
35. Zhang L, "Lineage tracking reveals dynamic relationships of T cells in colorectal cancer", Nature, 564, pp.268~272 (2018)
36. Miyazaki K, "The role of the basic helixloop-helix transcription factor Dec1 in the regulatory T cells", J Immunol, 185, pp.7330~7339 (2010)
37. Lin CC, "Bhlhe40 controls cytokine production by T cells and is essential for pathogenicity in autoimmune neuroinflammation", Nat Commun, 5, pp.3551~ (2014)
38. Zhang L, "Single-cell analyses inform mechanisms of myeloid-targeted therapies in colon cancer", Cell, 181, pp.442~459 (2020)
39. de Vries NL, "High-dimensional cytometric analysis of colorectal cancer reveals novel mediators of antitumour immunity", Gut, 69, pp.691~703 (2020)
40. Norton SE, "High-dimensional mass cytometric analysis reveals an increase in effector regulatory T cells as a distinguishing feature of colorectal tumors", J Immunol, 202, pp.1871~1884 (2019)
41. Di J, "Phenotype molding of T cells in colorectal cancer by single-cell analysis", Int J Cancer, 146, pp.2281~2295 (2020)
42. Boland CR, "Microsatellite instability in colorectal cancer", Gastroenterology, 138, pp.2073~2087 (2010)
43. Dudley JC, "Microsatellite instability as a biomarker for PD-1 blockade", Clin Cancer Res, 22, pp.813~820 (2016)
44. Llosa NJ, "The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints", Cancer Discov, 5, pp.43~51 (2015)
45. Le DT, "Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade", Science, 357, pp.409~413 (2017)
46. Schrock AB, "Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSIhigh metastatic colorectal cancer", Ann Oncol, 30, pp.1096~1103 (2019)
47. Klempner SJ, "Tumor mutational burden as a predictive biomarker for response to immune checkpoint inhibitors : a review of current evidence", Oncologist, 25, pp.e147~e159 (2020)
48. Chalmers ZR, "Analysis of 100, 000human cancer genomes reveals the landscape of tumor mutational burden", Genome Med, 9, pp.34~ (2017)
49. Merino DM, "Establishing guidelines to harmonize tumor mutational burden(TMB) : in silico assessment of variation in TMB quantification across diagnostic platforms : phase I of the Friends of Cancer Research TMB Harmonization Project", J Immunother Cancer, 8, pp.e000147~ (2020)
50. Cancer Genome Atlas Network, "Comprehensive molecular characterization of human colon and rectal cancer", Nature, 487, pp.330~337 (2012)
51. Parikh AR, "Analysis of DNA damage response gene alterations and tumor mutational burden across 17, 486 tubular gastrointestinal carcinomas : implications for therapy", Oncologist, 24, pp.1340~1347 (2019)
52. Lee DW, "Tumor mutation burden and prognosis in patients with colorectal cancer treated with adjuvant fluoropyrimidine and oxaliplatin", Clin Cancer Res, 25, pp.6141~6147 (2019)
53. Vanderwalde A, "Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11, 348 patients", Cancer Med, 7, pp.746~756 (2018)
54. Liu Y, "Comparative molecular analysis of gastrointestinal adenocarcinomas", Cancer Cell, 33, pp.721~735 (2018)
55. Hino H, "Clinicopathological and mutational analyses of colorectal cancer with mutations in the POLE gene", Cancer Med, 8, pp.4587~4597 (2019)
56. Domingo E, "Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer : a retrospective, pooled biomarker study", Lancet Gastroenterol Hepatol, 1, pp.207~216 (2016)
57. Wang C, "Immune profiling of microsatellite instability-high and polymerase epsilon(POLE)-mutated metastatic colorectal tumors identifies predictors of response to anti-PD-1 therapy", J Gastrointest Oncol, 9, pp.404~415 (2018)
58. Robyn Silberman, "Complete and prolonged response to immune checkpoint blockade in POLE-mutated colorectal cancer", JCO Precision Oncology, (3), pp.1~5 (2019), American Society of Clinical Oncology (ASCO)[DOI]
59. De Sousa EM, "Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions", Nat Med, 19, pp.614~618 (2013)
60. Sadanandam A, "A colorectal cancer classification system that associates cellular phenotype and responses to therapy", Nat Med, 19, pp.619~625 (2013)
61. Marisa L, "Gene expression classification of colon cancer into molecular subtypes : characterization, validation, and prognostic value", PLoS Med, 10, pp.e1001453~ (2013)
62. Karpinski P, "Immunological landscape of consensus clusters in colorectal cancer", Oncotarget, 8, pp.105299~105311 (2017)
63. Soldevilla B, "The correlation between immune subtypes and consensus molecular subtypes in colorectal cancer identifies novel tumour microenvironment profiles, with prognostic and therapeutic implications", Eur J Cancer, 123, pp.118~129 (2019)
64. Thorsson V, "The immune landscape of cancer", Immunity, 48, pp.812~830 (2018)
65. Rosenbaum MW, "PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes", Mod Pathol, 29, pp.1104~1112 (2016)
66. Lee LH, "Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma", Mod Pathol, 29, pp.1433~1442 (2016)
67. Kim JH, "Characterisation of PD-L1-positive subsets of microsatellite-unstable colorectal cancers", Br J Cancer, 115, pp.490~496 (2016)
68. Inaguma S, "Clinicopathologic profile, immunophenotype, and genotype of CD274(PD-L1)-positive colorectal carcinomas", Mod Pathol, 30, pp.278~285 (2017)
69. Eriksen AC, "Programmed death ligand-1 expression in stage II colon cancer-experiences from a nationwide populationbased cohort", BMC Cancer, 19, pp.142~ (2019)
70. Li Y, "The prognostic and clinicopathological roles of PD-L1 expression in colorectal cancer : a systematic review and meta-analysis", Front Pharmacol, 10, pp.139~ (2019)
71. Yamada R, "Differences in histological features and PD-L1 expression between sporadic microsatellite instability and Lynch-syndrome-associated disease in Japanese patients with colorectal cancer", Int J Clin Oncol, 23, pp.504~513 (2018)
72. Ganesh K, "Immunotherapy in colorectal cancer : rationale, challenges and potential", Nat Rev Gastroenterol Hepatol, 16, pp.361~375 (2019)

관련 논문AI추천